Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An international collaborative decision analysis

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2662-2670

  Koreth, John ^a   Pidala, Joseph ^b   Perez, Waleska S ^c   Deeg, H Joachim ^d   Garcia Manero, Guillermo ^e   Malcovati, Luca ^f   Cazzola, Mario ^f   Park, Sophie ^g   Itzykson, Raphael ^h   Ades, Lionel ^h   Fenaux, Pierre ^h   Jadersten, Martin ⁱ   Hellstrom Lindberg, Eva ⁱ   Gale, Robert Peter ^j,k   Beach, C L ^j   Lee, Stephanie J ^d   Horowitz, Mary M ^c   Greenberg, Peter L ^l   Tallman, Martin S ^i,m   DiPersio, John F ⁿ   Bunjes, Donald ^o   Weisdorf, Daniel J ^p   Cutler, Corey ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITÉ PARIS 13   (France)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j CELGENE CORPORATION   (United States)

^k IMPERIAL COLLEGE LONDON   (United Kingdom)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY HOSPITAL ULM   (Germany)

^p UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE;

5Q- SYNDROME; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; FEMALE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; SURVIVAL TIME; T CELL DEPLETION; DECISION SUPPORT SYSTEM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL COOPERATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROBABILITY; PROCEDURES;

AGED; DECISION SUPPORT TECHNIQUES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERNATIONAL COOPERATION; MALE; MARKOV CHAINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; TRANSPLANTATION CONDITIONING;

EID: 84883553488     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.8652     Document Type: Article

References (55)

1. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 [Erratum: Blood 91:1100, 1998]
2. Rollison DE, Howlader N, Smith MT, et al: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52, 2008
3. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
4. Mufti GJ, Stevens JR, Oscier DG, et al: Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 59:425-433, 1985
5. Coiffier B, Adeleine P, Gentilhomme O, et al: Myelodysplastic syndromes: A multiparametric study of prognostic factors in 336 patients. Cancer 60:3029-3032, 1987
6. Sanz GF, Sanz MA, Vallespí T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989
7. Aul C, Gattermann N, Heyll A, et al: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59, 1992
8. Morel P, Hebbar M, Lai JL, et al: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315-1323, 1993
9. Maschek H, Gutzmer R, Choritz H, Georgii A: Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 53:280-287, 1994
10. Cunningham I, MacCallum SJ, Nicholls MD, et al: The myelodysplastic syndromes: An analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 90:602-606, 1995
11. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
12. Balduini CL, Guarnone R, Pecci A, et al: International prognostic scoring system and other prognostic systems for myelodysplastic syndromes. Blood 90:4232-4234, 1997
13. Estey E, Keating M, Pierce S, et al: Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. Blood 90:2843-2846, 1997
14. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
15. Cazzola M, Malcovati L: Myelodysplastic syndromes: Coping with ineffective hematopoiesis. N Engl J Med 352:536-538, 2005
16. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005
17. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007
18. Nimer SD: Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 24:2576-2582, 2006
19. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
20. Fenaux P, Giagounidis A, Selleslag D, et al: A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:3765-3776, 2011
21. Greenberg PL, Attar E, Bennett JM, et al: NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes. J Natl Compr Canc Netw 9:30-56, 2011
22. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008
23. Jädersten M, Malcovati L, Dybedal I, et al: Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613, 2008
24. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903, 2006
25. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
26. Fenaux P, Mufti GJ, Santini V, et al: Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study. Blood 110, 2007 (abstr 817)
27. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207, 2002
28. Anderson JE, Appelbaum FR, Schoch G, et al: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14: 220-226, 1996
29. Anderson JE, Appelbaum FR, Schoch G, et al: Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 87:51-58, 1996
30. Arnold R, de Witte T, van Biezen A, et al: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey-European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21:1213-1216, 1998
31. Runde V, de Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome-Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:255-261, 1998
32. de Witte T, Hermans J, Vossen J, et al: Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620-630, 2000
33. Sierra J, Pé rez WS, Rozman C, et al: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
34. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor marrow transplantation for myelodysplastic syndromes: Outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002
35. Scott BL, Sandmaier BM, Storer B, et al: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 20:128-135, 2006
36. Scott B, Deeg HJ: Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract Res Clin Haematol 19:519-533, 2006
37. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004
38. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12:1047-1055, 2006
39. Nakamura R, Rodriguez R, Palmer J, et al: Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 40:843-850, 2007
40. Feinstein LC, Sandmaier B: Nonmyeloablative transplantation, in Soiffer R (ed): Stem Cell Transplantation for Hematologic Malignancies. Totowa, NJ, Humana Press, 2004, pp. 469-482
41. Platzbecker U, Schetelig J, Finke J, et al: Allogeneic hematopoietic cell transplantation in patients aged 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: Comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 18:1415-1421, 2012
42. Weinstein MC, Fineberg HV, Elstein AS, et al: Clinical Decision Analysis. Philadelphia, PA, Saunders, 1980
43. Djulbegovic B, Hendler FJ, Hamm J, et al: Residual mediastinal mass after treatment of Hodgkin's disease: A decision analysis. Med Hypotheses 38:166-175, 1992
44. Lee SJ, Kuntz KM, Horowitz MM, et al: Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis. Ann Intern Med 127:1080-1088, 1997
45. Ng AK, Weeks JC, Mauch PM, et al: Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol 17:3577-3585, 1999
46. Kurosawa S, Yamaguchi T, Miyawaki S, et al: A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood 117:2113-2120, 2011
47. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
48. Itzykson R, Thé pot S, Quesnel B, et al: Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117:403-411, 2011
49. Kantarjian HM, O'Brien S, Shan J, et al: Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109: 265-273, 2007
50. Pidala J, Anasetti C, Kharfan-Dabaja MA, et al: Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1415-1421, 2009
51. Pan F, Peng S, Fleurence R, et al: Economic analysis of decitabine versus best supportive care in the treatment of intermediate-And high-risk myelodysplastic syndromes from a US payer perspective. Clin Ther 32:2444-2456, 2010
52. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878-1887, 2010
53. Koreth J, Aldridge J, Kim HT, et al: Reducedintensity conditioning hematopoietic stem cell transplantation in patients over 60 years: Hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 16:792-800, 2010
54. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496-2506, 2011
55. Alessandrino EP, Della Porta MG, Malcovati L, et al: Decision analysis of allogeneic stem cell transplantation in patients with myelodysplastic syndrome stratified according to the WHO classification-based prognostic scoring system (WPSS). Blood 118, 2011 (abstr 116)